ATE446297T1 - Lactamverbindungen und deren medizinische verwendung - Google Patents

Lactamverbindungen und deren medizinische verwendung

Info

Publication number
ATE446297T1
ATE446297T1 AT01998549T AT01998549T ATE446297T1 AT E446297 T1 ATE446297 T1 AT E446297T1 AT 01998549 T AT01998549 T AT 01998549T AT 01998549 T AT01998549 T AT 01998549T AT E446297 T1 ATE446297 T1 AT E446297T1
Authority
AT
Austria
Prior art keywords
diabetic
medical use
lactam compounds
agent
adiposis
Prior art date
Application number
AT01998549T
Other languages
German (de)
English (en)
Inventor
Y Iino
T Ikenoue
N Kondo
H Matsueda
T Hatanaka
R Hirama
Y Masuzawa
F Ohta
A Yamazaki
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE446297T1 publication Critical patent/ATE446297T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
AT01998549T 2000-12-01 2001-11-29 Lactamverbindungen und deren medizinische verwendung ATE446297T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
ATE446297T1 true ATE446297T1 (de) 2009-11-15

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998549T ATE446297T1 (de) 2000-12-01 2001-11-29 Lactamverbindungen und deren medizinische verwendung

Country Status (26)

Country Link
US (3) US7153850B2 (enExample)
EP (1) EP1346993B1 (enExample)
JP (2) JP3826400B2 (enExample)
KR (1) KR100826818B1 (enExample)
CN (2) CN100577651C (enExample)
AT (1) ATE446297T1 (enExample)
AU (3) AU1850202A (enExample)
BG (1) BG107857A (enExample)
BR (1) BR0115852A (enExample)
CA (1) CA2430124C (enExample)
CZ (1) CZ20031520A3 (enExample)
DE (1) DE60140270D1 (enExample)
ES (1) ES2331299T3 (enExample)
HU (1) HUP0400806A3 (enExample)
IL (1) IL156158A0 (enExample)
MX (1) MXPA03004876A (enExample)
NO (1) NO325401B1 (enExample)
NZ (1) NZ526164A (enExample)
PL (1) PL362835A1 (enExample)
RU (1) RU2287530C2 (enExample)
SK (1) SK6582003A3 (enExample)
TW (1) TWI241302B (enExample)
UA (1) UA76969C2 (enExample)
WO (1) WO2002044180A1 (enExample)
YU (1) YU42603A (enExample)
ZA (1) ZA200304100B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100577651C (zh) * 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
WO2004069259A1 (ja) * 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
JP4711228B2 (ja) 2003-10-31 2011-06-29 味の素株式会社 複素環を有する新規縮合多環式化合物及びその医薬用途
WO2005068467A1 (ja) * 2004-01-14 2005-07-28 Ajinomoto Co., Inc. 新規縮環化合物
CN101039946B (zh) * 2004-10-13 2010-12-08 霍夫曼-拉罗奇有限公司 用作用于cdk2和血管生成的抑制剂及用于治疗乳腺、结肠、肺和前列腺癌的二取代吡唑并苯并二氮杂*类
EP1878734A4 (en) 2005-04-28 2010-02-17 Ajinomoto Kk NEW COMPOUND LACTAME
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
CN107106572B (zh) * 2014-12-22 2021-01-12 Ea制药株式会社 角膜上皮障碍治疗剂
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
WO2020151671A1 (en) * 2019-01-23 2020-07-30 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
AU8592598A (en) 1997-07-30 1999-02-22 Wyeth Tricyclic vasopressin agonists
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
CN100577651C (zh) 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
WO2004069259A1 (ja) 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤

Also Published As

Publication number Publication date
ZA200304100B (en) 2004-08-22
WO2002044180A1 (en) 2002-06-06
EP1346993A1 (en) 2003-09-24
HUP0400806A2 (hu) 2004-07-28
KR100826818B1 (ko) 2008-05-02
JPWO2002044180A1 (ja) 2004-04-02
PL362835A1 (en) 2004-11-02
CA2430124A1 (en) 2002-06-06
YU42603A (sh) 2006-03-03
AU1850202A (en) 2002-06-11
DE60140270D1 (de) 2009-12-03
HUP0400806A3 (en) 2007-11-28
AU2006241377B2 (en) 2009-01-08
NO20032439D0 (no) 2003-05-28
US7153850B2 (en) 2006-12-26
TWI241302B (en) 2005-10-11
CN1911915A (zh) 2007-02-14
EP1346993B1 (en) 2009-10-21
MXPA03004876A (es) 2004-01-27
NO20032439L (no) 2003-07-18
JP3826400B2 (ja) 2006-09-27
IL156158A0 (en) 2003-12-23
US7326701B2 (en) 2008-02-05
US20080096862A1 (en) 2008-04-24
CN1269818C (zh) 2006-08-16
EP1346993A4 (en) 2005-12-21
ES2331299T3 (es) 2009-12-29
US20060189597A1 (en) 2006-08-24
CZ20031520A3 (cs) 2003-10-15
UA76969C2 (en) 2006-10-16
RU2287530C2 (ru) 2006-11-20
SK6582003A3 (en) 2003-09-11
US7632830B2 (en) 2009-12-15
JP2006213732A (ja) 2006-08-17
US20040048847A1 (en) 2004-03-11
AU2006241377A1 (en) 2006-12-14
CA2430124C (en) 2011-01-11
BR0115852A (pt) 2003-12-23
NO325401B1 (no) 2008-04-21
NZ526164A (en) 2004-09-24
BG107857A (bg) 2004-06-30
JP4505753B2 (ja) 2010-07-21
CN100577651C (zh) 2010-01-06
CN1487940A (zh) 2004-04-07
KR20030051893A (ko) 2003-06-25
AU2002218502B2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
ATE446297T1 (de) Lactamverbindungen und deren medizinische verwendung
NL300985I1 (en) mogamulizumab
DE60022226D1 (de) Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
SE0100284D0 (sv) Medical communication system
ATE232862T1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
AU2001276689A1 (en) Novel remedies for cancer
ATE438626T1 (de) 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
DE59910758D1 (de) Transdermales pflaster, enthaltend mindestens einen die blutfettwerte beeinflussenden wirkstoff
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
NO985571L (no) Legemiddel for autoimmunsykdommer
DE60043783D1 (de) Metalloprotease mit aggrecanase-aktivität
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
TW200509980A (en) Parasiticidal composition
DE69941897D1 (de) Arzneimittel für nicht-cardiogene diastolische dysfunktion
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
EP1130018A4 (en) DRUGS FOR DRUG ADDICTION
DE69012742D1 (de) Azolderivate und fungizide Medikamente, diese als wirkende Komponente enthaltend.
FR2716193B1 (fr) Dérivés de 1[2-(1h-inden-3-yl)ethyl]-4-(naphtalen-1-yl)piperazine, leur préparation et leur application en thérapeutique.
AR035986A1 (es) Uso de derivados anti-convulsivos para la manufactura de un medicamento util para el tratamiento del temblor esencial
ATE285236T1 (de) Antivirale zusammensetzungen enthaltend yohimbin als therapeutischen wirkstoff
DK1273231T3 (da) Fungicid blanding
IL182125A0 (en) Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties